Global HLA Typing For Transplant Market Size, Trends & Growth Opportunity and By Type (Molecular Assays and Non-Molecular Assays), By Application (Diagnostic Applications and Research Applications), By End User (Hospitals & Transplant Centers, Commercial

Global HLA Typing For Transplant Market Size, Trends & Growth Opportunity and By Type (Molecular Assays and Non-Molecular Assays), By Application (Diagnostic Applications and Research Applications), By End User (Hospitals & Transplant Centers, Commercial Service Providers, and Research Laboratories and Academic Institutes), By Region and Forecast till 2027.

Global HLA Typing For Transplant Market

The Global HLA Typing For Transplant Market is expected to grow from US$ 775.5 Million in 2021 to US$ 1234.5 Million by 2027; it is estimated to grow at a CAGR of 8.06% from 2022 to 2027.

Market Overview

HLA typing is commonly referred as Human Leukocyte Antigen which is used to check how closely tissue of donor matches with tissue of recipient before transplantation. HLA are proteins which inherited from the parents. HLA matching helps in development and growth of new healthy food cells and also eliminates risk of post-transplant complication.

Market Drivers

Rise in number of transplant procedures is the key driving factor which is expected to boost the global HLA typing for transplant market growth. Furthermore, continuous technological advancements in HLA typing will have the positive impact on market growth. Moreover, rise in public-private funding for target research activities will fuel the market growth. In addition to that, increase in geriatric population will fuel the market growth. Also, rise in number of older adults are becoming organ donors which expected to propel the market growth.

Market Restraints

However, high cost of molecular tests used for HLA typing procedures is the major restraining factor which is expected to hamper the global HLA typing for transplant market growth. Also, significant gap between the number of organ donors and organs required annually will affect the market growth.

Market Opportunity

Target research activities are expected to receive more public-private funding in the future, which will present the market with a number of expansion opportunities. Moreover, it is predicted that the market will benefit greatly from technological developments in the area of transplant diagnostics. The market for human leukocyte antigen (HLA) typing for transplants will continue to grow in the future due to a number of technological developments and the quick transition from serological assays to gene-based HLA typing.

Impact of Covid-19

The market for HLA typing for transplants is expected to be significantly impacted by the COVID-19 epidemic. The COVID-19 outbreak is being fought by pharmaceutical and biotech companies working with governments around the world on everything from vaccine development to contingency plans for problems with the pharmaceutical supply chain. The research and development pipeline is currently home to numerous vaccine candidates and substances. In addition, Hydroxychloroquine was widely used to stop COVID-19. Manufacturers of COVID-19 management medications have a lot of opportunities because there is such a high demand for these treatments that many wealthy nations are running out of them.

Segmentation By Type: Global HLA Typing For Transplant Market is classified on the basis of Type into Molecular Assays and Non-Molecular Assays.

Segmentation By Application: Global HLA Typing For Transplant Market on the basis of Application into Diagnostic Applications and Research Applications.

Segmentation By End-user: Global HLA Typing For Transplant Market on the basis of End-user into Hospitals & Transplant Centers, Commercial Service Providers, and Research Laboratories and Academic Institutes.

Segmentation By Region: Global HLA Typing For Transplant Market is classified on the basis of Region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Market Key Players

Various key players are discussed in this report such as Thermo Fisher Scientific, F. Hoffman-La Roche Limited, Qiagen, Immucor, Abbott Laboratories Inc., Caredx, Inc., Illumina, Bio-Rad Laboratories, Alpha Biotech, Ltd., And Gendx.

Industrial Development

• Thermo Fisher Scientific's One Lambda brand and Natera, Inc. (NASDAQ: NTRA), a pioneer in non-invasive genetic testing and the analysis of cell-free DNA, announced a partnership in February 2019 to jointly distribute Natera's kidney transplant rejection test in the United States. One Lambda is a world leader in human leukocyte antigen (HLA) typing and antibody monitoring assays for transplantation.